CO2018000809A2 - Anticuerpos para cd40 - Google Patents

Anticuerpos para cd40

Info

Publication number
CO2018000809A2
CO2018000809A2 CONC2018/0000809A CO2018000809A CO2018000809A2 CO 2018000809 A2 CO2018000809 A2 CO 2018000809A2 CO 2018000809 A CO2018000809 A CO 2018000809A CO 2018000809 A2 CO2018000809 A2 CO 2018000809A2
Authority
CO
Colombia
Prior art keywords
antibodies
fcγriib
bind
administering
cancer
Prior art date
Application number
CONC2018/0000809A
Other languages
English (en)
Inventor
Brigitte Devaux
Brenda L Stevens
Bryan C Barnhart
Aaron P Yamniuk
Shannon L Okada
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56322325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018000809(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO2018000809A2 publication Critical patent/CO2018000809A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere anticuerpos agonistas, o porciones de unión al antígeno del mismo que se unen a CD40 humano. Tales anticuerpos comprenden opcionalmente regiones Fc con especificidad mejorada para FcγRIIb. La invención también proporciona métodos para el tratamiento de cáncer o infección crónica administrando los anticuerpos de la invención a un sujeto en necesidad del mismo.
CONC2018/0000809A 2015-06-29 2018-01-26 Anticuerpos para cd40 CO2018000809A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186076P 2015-06-29 2015-06-29
US201562252615P 2015-11-09 2015-11-09
PCT/US2016/039754 WO2017004006A1 (en) 2015-06-29 2016-06-28 Antibodies to cd40

Publications (1)

Publication Number Publication Date
CO2018000809A2 true CO2018000809A2 (es) 2018-04-19

Family

ID=56322325

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0000809A CO2018000809A2 (es) 2015-06-29 2018-01-26 Anticuerpos para cd40

Country Status (17)

Country Link
US (3) US20180142030A1 (es)
EP (1) EP3313880A1 (es)
JP (2) JP7350467B2 (es)
KR (1) KR102671348B1 (es)
CN (2) CN115838427A (es)
AU (2) AU2016285913B2 (es)
BR (1) BR112017027549A2 (es)
CA (1) CA2990012A1 (es)
CL (2) CL2017003427A1 (es)
CO (1) CO2018000809A2 (es)
EA (1) EA035268B1 (es)
HK (1) HK1252666A1 (es)
IL (1) IL256499B (es)
MX (2) MX2017016253A (es)
PE (1) PE20180315A1 (es)
WO (1) WO2017004006A1 (es)
ZA (1) ZA201708704B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2683406T3 (pl) 2011-03-11 2019-11-29 Beth Israel Deaconess Medical Ct Inc Przeciwciała anty-cd40 i ich zastosowania
WO2016023960A1 (en) 2014-08-12 2016-02-18 Alligator Bioscience Ab Combination therapies with anti cd40 antibodies
US10479838B2 (en) * 2015-06-29 2019-11-19 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
CN116063494A (zh) 2016-03-04 2023-05-05 洛克菲勒大学 具有增强的激动剂活性的cd40的抗体
PT3468997T (pt) 2016-06-08 2023-12-07 Debra Zack Tratamento de doenças relacionadas com igg4 com anticorpos anti-cd19 com ligação cruzada a cd32b
IL263834B2 (en) 2016-06-20 2024-01-01 Kymab Ltd Antibodies against PD-L1
ES2923143T3 (es) 2017-05-25 2022-09-23 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra CD40 y sus usos
MX2019014375A (es) 2017-06-01 2020-01-23 Jiangsu Hengrui Medicine Co Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
CN111788227A (zh) 2017-12-27 2020-10-16 百时美施贵宝公司 抗cd40抗体及其用途
KR102432046B1 (ko) * 2018-03-23 2022-08-12 일라이 릴리 앤드 캄파니 항-pd-l1 항체와의 조합을 위한 항-cd137 항체
WO2020014974A1 (en) 2018-07-20 2020-01-23 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
TW202021620A (zh) 2018-11-30 2020-06-16 大陸商江蘇恒瑞醫藥股份有限公司 一種cd40抗體藥物組合物及其用途
JP2022509156A (ja) * 2018-11-30 2022-01-20 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
US10570210B1 (en) * 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
EP3954705A4 (en) 2019-04-10 2023-06-07 Nankai University ANTI-CD40 ANTIBODIES AND ITS USE
WO2021183428A1 (en) 2020-03-09 2021-09-16 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
CA3172293A1 (en) * 2020-05-06 2021-11-11 Chia-Mao Wu Fusion proteins for immunotherapy against cancer and infectious diseases
CN115403670A (zh) * 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
EP4384276A1 (en) * 2021-08-10 2024-06-19 Apexigen, Inc. Biomarkers for cd40 agonist therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
EP2656073A4 (en) * 2010-12-20 2014-12-17 Univ Rockefeller MODULATION AGONISTIC TNFR ANTIBODY
KR102147548B1 (ko) 2011-02-25 2020-08-24 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
WO2015091655A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Combination therapy with an anti-ang2 antibody and a cd40 agonist
CA2943167A1 (en) 2014-03-24 2015-10-01 University Of Southampton Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
WO2016028810A1 (en) * 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
US10479838B2 (en) * 2015-06-29 2019-11-19 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
CN116063494A (zh) * 2016-03-04 2023-05-05 洛克菲勒大学 具有增强的激动剂活性的cd40的抗体

Also Published As

Publication number Publication date
US20190248911A1 (en) 2019-08-15
MX2017016253A (es) 2018-04-20
MX2022002504A (es) 2022-04-06
US20180142030A1 (en) 2018-05-24
KR20180021834A (ko) 2018-03-05
WO2017004006A1 (en) 2017-01-05
BR112017027549A2 (pt) 2018-09-11
JP2018526978A (ja) 2018-09-20
IL256499B (en) 2021-12-01
EA035268B1 (ru) 2020-05-22
AU2016285913B2 (en) 2022-06-16
CN107771184B (zh) 2022-11-01
JP7350467B2 (ja) 2023-09-26
CN107771184A (zh) 2018-03-06
CN115838427A (zh) 2023-03-24
HK1252666A1 (zh) 2019-05-31
CL2017003427A1 (es) 2018-05-04
AU2022228155A1 (en) 2022-11-10
JP2022028666A (ja) 2022-02-16
US20210054091A1 (en) 2021-02-25
EP3313880A1 (en) 2018-05-02
ZA201708704B (en) 2019-08-28
EA201890175A1 (ru) 2018-06-29
CL2022001189A1 (es) 2023-01-20
KR102671348B1 (ko) 2024-05-30
PE20180315A1 (es) 2018-02-09
US10844130B2 (en) 2020-11-24
AU2016285913A1 (en) 2018-02-15
IL256499A (en) 2018-02-28
CA2990012A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
CO2018000809A2 (es) Anticuerpos para cd40
UY36757A (es) Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
CY1124033T1 (el) Δοσολογια και χορηγηση μη φουκοζυλιωμενων αντισωματων anti-cd40
GT201700286A (es) Modulación y tratamiento inmunes de tumores sólidos con anticuerpos que se unen específicamente a cd38
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
CO2018001485A2 (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7 - h3 y cd3
CU20160101A7 (es) Inmunoglobulina con fab en tándem
ECSP17008984A (es) Tratamientos conjuntos con anticuerpos anti cd40
MX2018010672A (es) Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada.
EA201792413A1 (ru) Антитела против cd71, активируемые антитела против cd71 и способы их применения
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
BR112016016436A2 (pt) moléculas de anticorpo para tim-3 e usos das mesmas
PE20171556A1 (es) Agentes de union a cd123 y usos de estos
MX2016013218A (es) Molecula de unión al antígeno trifuncional.
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
CO2017003005A2 (es) Anticuerpos anti-mfi2
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
UY35493A (es) Métodos para el tratamiento de la osteogénesis imperfecta
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
BR112017000303A2 (pt) métodos para o tratamento de hipotensão
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.
AR105171A1 (es) Anticuerpos contra cd40 con actividad agonista mejorada
EA201891445A1 (ru) Молекулы антител, которые связываются с tnf-альфа
EA202090453A3 (ru) Антитела к cd40